They may offer the rationale for testing in our pre-clinical setting a combined therapy aiming to hit proliferation and survival of T-ALL cells but also to inhibit the induction of immunosuppression by using highly selective NF-κB inhibitors (such as p65 subunit inhibitors). Here, NFKB1 is linked to acute lymphoblastic leukemia.